- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 39/116 - Polyvalent bacterial antigens
Patent holdings for IPC class A61K 39/116
Total number of patents in this class: 299
10-year publication summary
|
15
|
26
|
4
|
24
|
10
|
23
|
15
|
14
|
11
|
4
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1701 |
57 |
| Pfizer Inc. | 3322 |
9 |
| Novartis AG | 11238 |
6 |
| Wyeth LLC | 691 |
5 |
| Sanofi Pasteur Inc. | 246 |
5 |
| University of Tennessee Research Foundation | 727 |
5 |
| Merck Sharp & Dohme LLC | 3689 |
5 |
| Wyeth Holdings LLC | 57 |
4 |
| Previwo AS | 21 |
4 |
| SK Bioscience Co., Ltd. | 103 |
4 |
| The Regents of the University of Michigan | 4409 |
3 |
| President and Fellows of Harvard College | 5792 |
3 |
| Baxalta GmbH | 113 |
3 |
| Baxalta Incorporated | 306 |
3 |
| Children's Hospital & Research Center at Oakland | 102 |
3 |
| Keio University | 1053 |
3 |
| Mount Sinai School of Medicine of New York University | 57 |
3 |
| Ohio State Innovation Foundation | 1770 |
3 |
| Serum Institute of India Private Limited | 94 |
3 |
| University of Maryland, Baltimore | 999 |
3 |
| Other owners | 165 |